National Health Act 1953 - Declaration under subsection 85(2AA) (No. PB 12 of 1996)

Overview

The National Health Act 1953 was enacted to provide a legislative framework for the administration of national health programs and services in Australia. This Act was introduced to address the need for a comprehensive national approach to health, aiming to ensure that Australians have access to necessary medical services and benefits. The Act was passed by the Commonwealth Parliament and its policy objective is to facilitate the provision of health services and benefits, particularly through the Pharmaceutical Benefits Scheme (PBS). One specific legislative instrument under this Act is the "Pharmaceutical Benefits Declaration under Subsection 85 (2AA)" issued in 1996. This declaration, made by David Trevor Graham, Assistant Secretary of the Pharmaceutical Benefits Branch, Department of Health and Family Services, removes certain drugs and medicinal preparations from the scope of the PBS, thereby ceasing their coverage under the Act. This amendment reflects ongoing assessments and adjustments to the list of subsidised medications, ensuring the scheme remains effective and aligned with current health needs and priorities.

Scope and Application

The Pharmaceutical Benefits Declaration under subsection 85 (2AA) of the National Health Act 1953 applies specifically to the cessation of certain drugs and medicinal preparations from the scope of Part VII of the Act. This legislative instrument specifies that the drugs and medicinal preparations listed in the Schedule, such as Fluclorolone Acetonide, will no longer be subject to the Pharmaceutical Benefits Scheme, which provides subsidised access to medicines for Australian citizens and permanent residents. The application of this Act is limited to the Commonwealth jurisdiction, governing the national framework for pharmaceutical benefits and their regulation across Australia. There are no stated exclusions or exemptions within the text of this specific declaration, and the geographic reach is national, affecting the entire country. Subordinate instruments may further define or extend the application of this Act, ensuring compliance and enforcement of the Pharmaceutical Benefits Scheme across various health care sectors.

Key Provisions

The main operative sections of the Declaration under subsection 85(2AA) of the National Health Act 1953, issued on 1 August 1996, focus on the removal of certain drugs and medicinal preparations from the scope of Part VII of the Act. Specifically, section 1 sets the date for the Declaration's operation, and section 2 outlines that the drugs and medicinal preparations listed in the Schedule will cease to be subject to Part VII of the National Health Act 1953. The Schedule includes the drug Fluclorolone Acetonide, which is the subject of this legislative change. The obligations and requirements imposed by this Declaration are primarily directed at the pharmaceutical industry and healthcare providers. Those involved in the provision, supply, or distribution of the specified drugs and medicinal preparations must ensure compliance with the changes outlined in the Declaration. This involves recognising that these drugs are no longer subject to the regulatory oversight and benefits outlined in Part VII of the National Health Act 1953. This change impacts how these drugs are financed, supplied, and potentially prescribed within the Australian healthcare system. The Declaration does not explicitly outline offences or penalties for breaches related to this specific legislative change. However, any non-compliance with the requirements of the National Health Act 1953, such as improper classification or supply of pharmaceutical products, could result in civil or criminal penalties under other sections of the Act. For instance, unauthorised supply of scheduled drugs might be prosecuted under sections that deal with general offences related to the supply of prohibited substances, which could attract fines or imprisonment as stipulated in the broader legislative framework. It is also important for entities to remain aware of any subsequent regulations or updates that might introduce additional obligations or consequences for non-compliance.